Inc. is a Silicon Valley R & D company with full ownership of IP
rights to a broad array of life science and software technologies. Its
business model emphasizes licensing and subscription revenue streams.
It is Transporin's goal to operate with a minimum of fixed overhead
costs. Corporate and academic collaborative projects are thus central
achieving its objectives, and joint R & D and business enterprises
between Transporin and partner organizations form the bulk of its
The company's area of strength lies in its above-average "innovation
index". Many of its technologies represent first-in-class concepts for
treating human disease and managing user knowledge and preference
through advanced software-based psychological and knowledge
Expert Journal(TM) is Transporin's flagship product in expert clinical
knowledge management, slated for launch in early 2015. The unit of
knowledge is the retrospective ("Retro") which provides, for the first
time, specific visual and compact data comparisons of key clinical data
from paired studies. The images are rendered on-the-go, on mobile
devices fully integrated with
Twitter(TM) and FaceBook(TM), providing real-time access. It is a way
to provide every user with the specific data
comparisons upon which experts typically base their decisions. Each
retro is deemed particularly important by a respected opinion leader in
relevant clinical field.
A second product area in development is eBook Match(TM) — an advanced,
proprietary psychological profiling tool matching users' worldviews
with writers and novels they would most likely enjoy reading. This tool
is the "missing link" in today's increasingly streamlined distribution
of content through retailers such as Amazon.
LIFE SCIENCE TECHNOLOGIES
Transporin's MBD transporter platform supports a range of extraordinary
products facilitating the targeted delivery of interventions inside the
human body. Its Transfexa(TM) line of generic reagents enables
researchers to deliver nucleic acids intracellularly both in vitro and
in vivo with a precision and effectiveness not hitherto possible
(and without requiring lipid-based carriers).
Ongoing collaborative R&D projects with academic and corporate
partners employ MBD transporter technology to functionalize antibody
and peptide-based biopharmaceutical drugs, including Nephrilin(TM) — a
first-in-class drug for the treatment of neuroinflammatory stress..
428 Oakmead Pkwy
Sunnyvale, CA 94085
business inquiries: firstname.lastname@example.org